Dihydroartemisinin-piperaquine holds promise as an option for malaria prevention in pregnancy.
Dihydroartemisinin-piperaquine holds promise as an option for malaria prevention in pregnancy.
复制标题
DOI：
10.1136/ebmed-2016-110438
复制
发表时间：
2016-08
期刊：
影响因子：
--
通讯作者：
Kuile FO
中科院分区：
文献类型：
--
作者：
Hill J;Kuile FO
Kakuru等人的试验是一项双盲、随机、对照、三臂试验，采用1：1：1分配，在妊娠12至20周的未感染HIV的孕妇中比较三个疗程的双氢青蒿素-哌喹和每月一次的双氢青蒿素-哌喹与标准三个疗程的磺胺嘧啶-乙胺嘧啶方案作为IPTp。这项研究是在乌干达的一个磺胺嘧啶-乙胺嘧啶耐药性高的地区进行的。主要结果是组织病理学证实的胎盘疟疾的患病率。次要结局包括症状性疟疾、寄生虫病、贫血和不良分娩结局。妇女和新生儿随访至分娩后6周。
MethodsThe trial by Kakuru et al was a double-blind, randomised, controlled, three-arm trial comparing three-course dihydroartemisinin–piperaquine and monthly dihydroartemisinin–piperaquine versus the standard three-course sulfadoxine–pyrimethamine regimen as IPTp among HIV-uninfected pregnant women between 12 and 20 weeks gestation, using a 1: 1: 1 allocation. The study was conducted in an area of high sulfadoxine–pyrimethamine resistance in Uganda. The primary outcome was the prevalence of histopathology-confirmed placental malaria. Secondary outcomes included symptomatic malaria, parasitaemia, anaemia and adverse birth outcomes. Women and newborns were followed up to 6 weeks post delivery.